Overview
The New Center of Pharma Public Affairs: The GLP-1 Advocacy Maze
The rapid rise of GLP-1 drugs like semaglutide and tirzepatide is more than a medical breakthrough. It has created one of the most complex and high-stakes public affairs challenges in recent memory. These treatments were first seen as a major step forward for type 2 diabetes. But their strong results in weight management have sparked a global debate. This has drawn intense media attention, huge patient demand, and fierce policy discussions. For pharmaceutical public affairs and market access teams, this is new ground. The challenge is not just showing clinical value. It’s about navigating a divided and fast-changing stakeholder world, especially among patient advocacy groups (PAGs).
Historically, diabetes PAGs spoke with a unified voice. They advocated for research, awareness, and access to essential medicines. The GLP-1 phenomenon, however, has changed everything. It has introduced new pressures that test old alliances and create new divisions. Key issues now include off-label use, supply shortages for diabetic patients, high costs, and how we define obesity as a disease. These topics are forcing advocacy groups to take complex and often conflicting positions. This case study explores these shifting patient advocacy trends. We will analyze how their changing stances are reshaping GLP-1 access policy and why old methods of stakeholder monitoring are no longer enough.
Advocacy Landscape
From One Voice to Many: The Old vs. New Advocacy Landscape
For decades, major organizations like the American Diabetes Association (ADA), Diabetes UK, and the International Diabetes Federation (IDF) were the main voices for patients. Their advocacy focused on a clear set of goals. They worked to secure research funding, run public awareness campaigns, and ensure affordable access to treatments. Their influence came from a clear, unified message aimed at regulators and payers.
The arrival of GLP-1s has broken this balance. This class of drugs serves two different but related groups: people with type 2 diabetes and people with obesity. This has led to a wider range of advocacy voices. Messages are no longer simple or united. We now see three main types of patient advocacy emerging. Each has its own goals and uses different tactics to influence GLP-1 access.
Archetype
The ‘Diabetes First’ Purists
This group often represents the core members of traditional diabetes PAGs. They are focused on protecting the interests of patients with type 2 diabetes. Their main argument is that the huge demand for GLP-1s for weight loss is causing critical supply shortages. This, they argue, harms access for the patients the drugs were first made for.
Core Narrative
“Ensure access for diagnosed patients first. Off-label use for cosmetic reasons puts lives at risk.”
Tactics
These groups use their established credibility with policymakers and the media. They share stories of diabetic patients who cannot get their prescriptions filled. They issue press releases urging manufacturers to prioritize the diabetes supply chain. They also lobby payers to create stricter rules, limiting use to diagnosed T2D patients to protect GLP-1 access for this core group.
Policy Impact
Their advocacy directly affects payer decisions, leading to tighter insurance controls. They also pressure regulators like the FDA and EMA to clarify approved uses, which can discourage off-label prescribing.
Archetype
The ‘Broad Access’ Champions
This group includes obesity-focused PAGs and more progressive diabetes organizations. They argue that obesity is a chronic disease, not a lifestyle choice. They see GLP-1s as a vital tool for managing it and related conditions, including type 2 diabetes. For them, separating the two conditions is unhelpful and wrong.
Core Narrative
“Obesity is a disease that deserves treatment. Denying GLP-1 access is discriminatory and hurts public health.”
Tactics
These advocates work to reduce the stigma of obesity. They build a scientific and economic case for wide coverage. They partner with medical societies to promote clinical guidelines that support using anti-obesity drugs. They show data to employers and health plans on the long-term cost savings of treating obesity. Their campaigns often feature powerful patient stories about the positive impact of weight loss.
Policy Impact
This group’s lobbying focuses on expanding insurance coverage, both public and private. In the US, they strongly support laws like the Treat and Reduce Obesity Act. In Europe, they work with national health technology assessment (HTA) bodies. They argue for the cost-effectiveness of covering GLP-1s for obesity, which is a key factor in securing market access.
Archetype
The ‘Equity and Accountability’ Watchdogs
A third, and growing, group of stakeholders focuses on the systemic issues of the GLP-1 boom. These include cost, fair access, and long-term safety. This group is made up of patient advocates, consumer rights groups, and academic researchers. They are often skeptical of the industry’s pricing and marketing.
Core Narrative
“These drugs could be revolutionary, but their high price makes them unavailable for most. We need transparency, fair pricing, and more long-term safety data.”
Tactics
These groups use data analysis and media outreach to examine list prices and manufacturer profits. They petition government bodies to investigate pricing. They call for research comparing GLP-1s to other treatments. They also raise public awareness about potential side effects and the unknowns of long-term use.
Policy Impact
Their work creates political pressure for drug price negotiations, like those in the US Inflation Reduction Act. It can also lead to more scrutiny from regulators. They create reputational risk for manufacturers and can change the public story from a ‘miracle drug’ to one of ‘corporate greed’, complicating efforts to secure favorable GLP-1 access.
Global Context
The Global Dimension of GLP-1 Access
These advocacy trends do not happen in a vacuum; they play out differently across the globe. The policy and reimbursement environments in the United States and Europe create distinct challenges and opportunities for securing GLP-1 access.
A Commercial-First System
In the U.S., the debate is heavily influenced by a commercial-first insurance system. Advocacy groups focus on influencing large employers and private payers, while also pushing for federal legislation to mandate Medicare coverage for obesity treatments. The narrative often centers on economic productivity and long-term healthcare savings.
HTA & Cost-Effectiveness
In contrast, European markets are often driven by national HTA bodies that conduct rigorous cost-effectiveness analyses. Here, the ‘Broad Access’ champions must present strong pharmacoeconomic data to bodies like Germany’s G-BA or the UK’s NICE. The political landscape is also different. Understanding the nuances between an EU Directive vs. Regulation is crucial, as it dictates how market-level decisions are made. Advocacy efforts must be tailored to each country’s specific health priorities and budget constraints, making a one-size-fits-all approach ineffective.
Strategic Implications
The Strategic Blind Spot: Why Static Stakeholder Maps Fail
The GLP-1 case is a clear warning that old public affairs tools are a liability. A simple spreadsheet of known experts and patient groups is dangerously out of date when the landscape changes so fast. An ally from last quarter might be a critic today. They could be influenced by a new study, a supply issue, or a change in funding. Relying on manual tracking and simple news alerts means you are always reacting, not anticipating.
To succeed in this environment, pharma teams need to shift from static maps to dynamic intelligence. The key questions are no longer just “What is a stakeholder?” They are now more complex:
Which story is getting the most attention in the media and online?
Which patient groups are successfully shaping payer decisions on GLP-1 access?
Are new, unexpected partnerships forming between obesity advocates and employer groups?
How are competitors’ actions changing the advocacy landscape?
Answering these questions requires a new method. It needs a system that can gather and analyze huge amounts of public information. This includes everything from policy debates and regulatory documents to patient forums and social media. The system must then structure this data into intelligence you can act on. You need a solution that reveals the perspectives, influence, and changing positions of every player. The entire process of how it works must be updated for this new reality.
The Solution
From Reactive Monitoring to Proactive Strategy with AI
The complexity of the GLP-1 access debate is not an exception; it is the new standard for new therapies. Whether in cancer, rare diseases, or neurology, public affairs teams face stakeholder worlds where influence is fluid and stories can change overnight.
Relying on manual work and basic monitoring tools is a strategic risk. The real opportunity is using AI-native intelligence systems. These systems can detect early signals, identify new trends, and map the entire influence network in real-time. This is how teams can stop chasing headlines and start shaping policy to secure market access.
The Bottom Line
The GLP-1 landscape shows that understanding the detailed positions of patient advocacy groups is a critical business need. The companies that succeed will be those who see the full picture. They will understand the ‘why’ behind the ‘what’ and act on intelligence, not just information.
Ready to monitor GLP-1 access policy?
Policy-Insider.AI’s stakeholder intelligence platform transforms reactive monitoring into proactive strategy.
Start a free pilot →No credit card required · Set up in minutes